Topic: Pfizer Biontech

Moderna files a lawsuit against Pfizer and BioNTech, alleging that their COVID-19 vaccine infringes on Moderna's foundational mRNA patents. Pfizer vows to defend its proprietary technology. The hosts discuss the timing of the lawsuit and the massive profits generated by both companies during the pandemic.

In a Washington Post interview, Pfizer CEO Albert Bourla admits that choosing mRNA technology was "counterintuitive" because the company had more experience with traditional vaccine methods. He reveals that his team "convinced" him to use mRNA despite it never having delivered a commercial product before the COVID-19 vaccine.

Pfizer and BioNTech were prominent sponsors of the 2022 Academy Awards, leading to theories that the slap controversy was a staged marketing event. Critics point to a Phase 3 clinical trial for an alopecia treatment conducted by Pfizer in August 2021 as a potential motive for the focus on the condition during the broadcast.

Leaked documents from Pfizer/BioNTech detail over 1,200 reported fatalities and numerous adverse events following vaccination. The hosts criticize the mainstream media and Fox News for failing to cover these internal reports. They liken their efforts to expose this information to "shoveling sand into the ocean" against a tide of media suppression.

Pfizer CEO Albert Bourla discusses the development of an Omicron-specific vaccine using a "pseudovirus" constructed in a laboratory. The hosts question why a synthetic version of the virus is used for testing rather than a natural isolate.

BioNTech CEO Ugur Sahin stated in an interview that he and his wife had not yet taken the COVID-19 vaccine, citing legal restrictions and priority lists. Sahin explained that company employees were legally barred from participating in their own clinical trials. He emphasized the need to maintain the "functionality" of his team to meet production goals of 1.3 billion doses, which the hosts interpret as a desire to avoid potential side effects that could hinder productivity.

A whistleblower report from the Pfizer supply chain reveals that the company is retiring the "purple cap" BioNTech vaccine in favor of the "gray cap" Comirnaty. This transition from Emergency Use Authorization (EUA) to a licensed product is seen as a move to clear inventory and potentially block competitors like Moderna and Janssen, who rely on EUA status. The move also paves the way for the approval of Pfizer's therapeutic pill, Paxlovid.

The legal framework for Emergency Use Authorization (EUA) is examined, noting that such authorization requires the absence of an approved alternative. There is speculation that the FDA avoids full approval of certain vaccines to maintain the EUA status for the broader market.

The FDA's full approval of the Pfizer-BioNTech vaccine, rebranded as Comirnaty, has created confusion regarding legal liability. While Comirnaty is approved, the existing stock of Pfizer vaccines remains under Emergency Use Authorization (EUA), which maintains a liability shield for the manufacturer. Critics argue the approval process bypassed traditional advisory committee discussions to expedite mandates.

Reports from France 24 and RT suggest a potential smear campaign against the Pfizer-BioNTech vaccine involving social media influencers. While Western outlets attribute the campaign to Russia-linked agencies, the discussion posits that Pfizer may be preemptively discrediting a study showing higher mortality rates compared to other vaccines. The use of Russia as a geopolitical scapegoat for domestic issues is criticized.

European Commission President Ursula von der Leyen announces a new contract with BioNTech-Pfizer for the years 2022 and 2023. The agreement secures 1.8 billion doses of the COVID-19 vaccine for the European Union. The hosts suggest this indicates a long-term plan for continued vaccination cycles.

The Pfizer-BioNTech vaccine has been officially branded as "Comirnaty" in Europe, though it is still widely referred to by the manufacturer's name in the US. This branding strategy is compared to "Xerox" or "Kleenex," where the company name becomes synonymous with the product, solidifying Pfizer's market dominance.

An examination of the eight-page Pfizer BioNTech COVID-19 vaccine handout reveals that the product lacks formal FDA approval and operates under Emergency Use Authorization. The document lists ingredients including mRNA, lipids, polyethylene glycol, and sucrose, while noting that the duration of protection remains unknown. The text explicitly states that refusing the vaccine will not alter a patient's standard medical care, raising questions about the legality of future vaccine passports.

Pfizer reported a $15 billion sales forecast for its COVID-19 vaccine in 2021, despite the product only having Emergency Use Authorization rather than full FDA approval. Meanwhile, Johnson & Johnson announced its one-shot vaccine is 66% effective at preventing moderate to severe illness. Unlike mRNA options, the J&J and AstraZeneca vaccines use more traditional viral vector technology.

The European Union began its coordinated vaccine rollout, with Hungary and Germany administering the first shots a day ahead of the official block-wide start. Each of the 27 member nations received an initial shipment of 10,000 doses. Mass vaccination efforts across the EU are expected to scale up in January 2021.

The Pfizer vaccine requires ultra-cold storage at minus 70 degrees Celsius, presenting significant logistical challenges for local administration. Additionally, Pfizer and BioNTech reported a cyber attack on the European Medicines Agency targeting vaccine-related data, with various foreign nations named as potential suspects.

President-elect Joe Biden introduced his coronavirus response team and outlined a goal to administer 100 million vaccine shots within his first 100 days in office. The FDA found the Pfizer-BioNTech vaccine successful in clinical trials, moving it closer to emergency use authorization. Reports from Democracy Now highlighted potential side effects from the second dose, including chills and headaches, as distribution is expected to begin within days of approval.

The Pfizer vaccine was developed in partnership with BioNTech, a German startup founded by Turkish immigrants. Media reports have framed this collaboration as a success story for globalization and a testament to international cooperation against a borderless disease. The narrative emphasizes the diverse origins of the scientists behind the first widely authorized mRNA vaccine.

Dr. Anthony Fauci addresses public skepticism regarding the rapid development of COVID-19 vaccines, attributing the speed to scientific advances in genetic sequencing rather than compromised safety. He expresses concern over a segment of the population that views the pandemic as "fake news" despite rising death tolls.

BioNTech, a German company founded by a Turkish couple and backed by the Gates Foundation, is the primary developer of the mRNA technology used in the Pfizer vaccine. Originally focused on individualized cancer immunotherapy, BioNTech is now applying its mRNA platform to infectious diseases like COVID-19 and Zika. Critics point to the rapid IPO and high-profile investments as evidence of a financial agenda behind the global vaccination push.